Amarin Corp. PLC (AMRN) Shares Down 2%
Amarin Corp. PLC (NASDAQ:AMRN)’s share price traded down 2% during mid-day trading on Friday . The company traded as low as $3.01 and last traded at $3.01, with a volume of 919,753 shares. The stock had previously closed at $3.07.
A number of equities analysts have issued reports on the company. Jefferies Group reiterated a “buy” rating and set a $3.50 target price on shares of Amarin Corp. PLC in a report on Thursday, July 7th. Zacks Investment Research cut Amarin Corp. PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Amarin Corp. PLC in a report on Monday, August 8th.
The company has a 50-day moving average price of $2.79 and a 200-day moving average price of $2.01. The firm’s market capitalization is $568.42 million.
Amarin Corp. PLC (NASDAQ:AMRN) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06. The business had revenue of $32.82 million for the quarter, compared to the consensus estimate of $29.97 million. The company’s revenue was up 85.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.15) earnings per share. Analysts anticipate that Amarin Corp. PLC will post ($0.46) earnings per share for the current year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.